摘要
By the end of 1980,Japanese groups had started programs with ABO-incomparible kidney transplantation as a consequence of the very limited supply of cadaveric organs for transplantation.Since then,they have done successful transplantations across the blood type barrier in combina-tion with plasmapheresis and splenectomy.In Japan,the strategy for ABO-incompatible transplantation has changed with the development of the tacrolimus(FK)/mycophenolate mofetil(MMF)combination in 2000 and rituximab in 2005.1 In addition,preoperative 1-week administration of FK/MMF produced much more excellent results.Current graft survival(2005-2013)was almost over 90%in both ABO-incompatible at 9-year follow-up,which was comparable to ABO-compatible kidney trans-plantations.
